Session » Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1107

Are Rheumatologists Correctly Identifying and Controlling Traditional Cardiovascular Risk Factors?

9:00AM-11:00AM: Abstract Number: 1079

Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018

9:00AM-11:00AM: Abstract Number: 1080

Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience

9:00AM-11:00AM: Abstract Number: 1082

Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea

9:00AM-11:00AM: Abstract Number: 1078

Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 1089

Causes of Death in ANCA-Associated Vasculitis According to ANCA Type

9:00AM-11:00AM: Abstract Number: 1081

Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries

9:00AM-11:00AM: Abstract Number: 1101

Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database

9:00AM-11:00AM: Abstract Number: 1088

Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration

9:00AM-11:00AM: Abstract Number: 1092

Efficacy and Safety of Dose Adjustment Based on Patients’ Body Size in Low Dose Intravenous CYC Treatment for Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1098

Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study

9:00AM-11:00AM: Abstract Number: 1102

Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjogren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance

9:00AM-11:00AM: Abstract Number: 1094

EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases

9:00AM-11:00AM: Abstract Number: 1087

Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)

9:00AM-11:00AM: Abstract Number: 1104

Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study

9:00AM-11:00AM: Abstract Number: 1090

Identification of a Distinct Intestinal Behçet’s Disease Cluster in Japan: A Nationwide Retrospective Observational Study

9:00AM-11:00AM: Abstract Number: 1076

Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 1096

Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks

9:00AM-11:00AM: Abstract Number: 1077

Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications

9:00AM-11:00AM: Abstract Number: 1100

Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1083

Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1084

Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1103

Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US

9:00AM-11:00AM: Abstract Number: 1085

Probiotic Use and Psoriatic Arthritis Disease Activity

9:00AM-11:00AM: Abstract Number: 1086

Psoriatic Arthritis – Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis

9:00AM-11:00AM: Abstract Number: 1105

Relationships Among Cognitive Emotion Regulation, Body Image, Family and Marital Function and Quality of Life in Chinese Female Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1091

Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry

9:00AM-11:00AM: Abstract Number: 1106

Systemic Lupus Erythematosus and Sjögren’s Syndrome in the Agricultural Health Study: Lower Risk Associated with Childhood Farm Residence and Raising Livestock

9:00AM-11:00AM: Abstract Number: 1075

The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1095

The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1099

The Safety of Pulse Therapy- Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1093

The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)

9:00AM-11:00AM: Abstract Number: 1097

Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].